Fulgent Genetics and Privia Health Group Compared

Analysts weigh in on the medical companies' performance and outlook

Published on Feb. 13, 2026

Got story updates? Submit your updates here. ›

Privia Health Group (NASDAQ:PRVA) and Fulgent Genetics (NASDAQ:FLGT) are both medical companies, but analysts are divided on which is the better stock. The companies were compared based on factors like profitability, risk, valuation, and analyst recommendations.

Why it matters

As investors weigh options in the healthcare sector, understanding the relative strengths and weaknesses of Privia Health Group and Fulgent Genetics can help inform investment decisions. The analysis highlights key differences between the two companies that may impact their future performance.

The details

The analysis found that Privia Health Group has higher revenue and earnings than Fulgent Genetics, but Fulgent Genetics is trading at a lower price-to-earnings ratio, making it more affordable. Privia Health Group also has a stronger consensus rating from analysts and higher projected upside potential. On profitability metrics like net margins, return on equity, and return on assets, Privia Health Group outperformed Fulgent Genetics. In terms of risk, both companies have stocks that are less volatile than the overall market, with Privia Health Group's being slightly less volatile.

  • The analysis was published on February 13, 2026.

The players

Privia Health Group

A national physician-enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care.

Fulgent Genetics

A provider of clinical diagnostic and therapeutic development solutions, including molecular diagnostic testing, genetic testing, and oncology tests and services.

Got photos? Submit your photos here. ›

The takeaway

The analysis suggests that Privia Health Group may be the more favorable investment option compared to Fulgent Genetics, based on its stronger financial performance, lower volatility, and more positive analyst sentiment. However, investors should continue to monitor both companies' developments and competitive positioning within the evolving healthcare landscape.